Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine
Joint Authors
Nyakas, Marta
Sæbøe-Larssen, Stein
Mobergslien, Anne
Aamdal, Steinar
Kvalheim, Gunnar
Sioud, Mouldy
Source
Issue
Vol. 2016, Issue 2016 (31 Dec. 2016), pp.1-7, 7 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2016-07-18
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Abstract EN
Indoleamine 2,3-dioxygenase (IDO) expression in dendritic cells (DCs) inhibits T-cell activation and promotes T-cell differentiation into regulatory T-cells.
Moreover, IDO expression promotes resistance to immunotherapies targeting immune checkpoints such as the cytotoxic T lymphocyte antigen-4 (CTLA-4).
Here, a patient with metastatic melanoma pretreated with ipilimumab, an anti-CTLA-4 blocking antibody, was vaccinated with IDO-silenced DCs cotransfected with mRNA for survivin or hTERT tumour antigens.
During vaccination, T-cell responses to survivin and hTERT tumour antigens were generated, and a certain degree of clinical benefit was achieved, with a significant reduction in lung, liver, and skin metastases, along with a better performance status.
T-cell responses against MART-1 and NY-ESO-1 tumour antigens were also detected in the peripheral blood.
The patient also mounted an antibody response to several melanoma proteins, indicating diversification of the antitumour immunity in this patient.
The identification of such serum antibody-reacting proteins could facilitate the discovery of tumour neoantigens.
American Psychological Association (APA)
Sioud, Mouldy& Nyakas, Marta& Sæbøe-Larssen, Stein& Mobergslien, Anne& Aamdal, Steinar& Kvalheim, Gunnar. 2016. Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine. Case Reports in Medicine،Vol. 2016, no. 2016, pp.1-7.
https://search.emarefa.net/detail/BIM-1101197
Modern Language Association (MLA)
Sioud, Mouldy…[et al.]. Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine. Case Reports in Medicine No. 2016 (2016), pp.1-7.
https://search.emarefa.net/detail/BIM-1101197
American Medical Association (AMA)
Sioud, Mouldy& Nyakas, Marta& Sæbøe-Larssen, Stein& Mobergslien, Anne& Aamdal, Steinar& Kvalheim, Gunnar. Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine. Case Reports in Medicine. 2016. Vol. 2016, no. 2016, pp.1-7.
https://search.emarefa.net/detail/BIM-1101197
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1101197